AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Serina Therapeutics, Inc.
XASE · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00HCXQ7C9
1.65▼ 0.11 (-6.25%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
1.76
Day's Range
1.65 – 1.76
52-Week Range
1.21 – 5.29
Volume
8,001
Avg Volume
34.1K
Share Statistics
Shares Outstanding
Employees
16
Exchange
XASE
Listed
2024-03-27
Share count as of August 10, 2026

Serina Therapeutics, Inc. (SER) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Serina Therapeutics, Inc. (SER)
What is Serina Therapeutics, Inc.'s Market Cap?
Serina Therapeutics, Inc.'s Market Cap is $41.9M, based on as-reported figures from SEC (XBRL) filings.
What is Serina Therapeutics, Inc.'s Revenue (TTM)?
Serina Therapeutics, Inc.'s Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Serina Therapeutics, Inc.'s Net Income (TTM)?
Serina Therapeutics, Inc.'s Net Income (TTM) is -$21.4M, based on as-reported figures from SEC (XBRL) filings.
What is Serina Therapeutics, Inc.'s EBITDA?
Serina Therapeutics, Inc.'s EBITDA is -$25.6M, based on as-reported figures from SEC (XBRL) filings.
What is Serina Therapeutics, Inc.'s Diluted EPS (TTM)?
Serina Therapeutics, Inc.'s Diluted EPS (TTM) is -0.84, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · SERAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
REVENUES
Total revenues—
YoY growth-100.0%—+100.0%-100.0%
OPERATING EXPENSES
Research and development
General and administrative
Total operating expenses
% of revenue————
Loss from operations—
% of revenue————
OTHER INCOME (EXPENSE), NET
Interest expense
Change in fair value of warrants
Change in fair value of tranche liability——
Loss on extinguishment of financial commitment assets and contingent warrants, net——
Other income, net
Total other income (expense), net
NET LOSS
% of revenue————
Less: Net loss attributable to noncontrolling interest
NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC.
% of revenue————
NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDERS——
NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDER, BASIC (in usd per share)—
NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDER, DILUTED (in usd per share)—